Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol

PurposeThe Chinese Children’s Cancer Group developed the CCCG-NB-2014 study to formulate optimal treatment strategies for high-risk (HR) neuroblastoma (NB). The safety and efficacy of this protocol were evaluated.MethodPatients with newly diagnosed neuroblastoma and defined as HR according to the Ch...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dongdong Zhang, Natasha Mupeta Kaweme, Peng Duan, Youhong Dong, Xiaojun Yuan
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	neuroblastoma high risk CCCG-NB-2014 overall survival N-myc Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/706ab05b14704fc5bdf3d6b3329b833c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:706ab05b14704fc5bdf3d6b3329b833c
record_format	dspace
spelling	oai:doaj.org-article:706ab05b14704fc5bdf3d6b3329b833c2021-11-15T06:40:04ZUpfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol2234-943X10.3389/fonc.2021.745794https://doaj.org/article/706ab05b14704fc5bdf3d6b3329b833c2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.745794/fullhttps://doaj.org/toc/2234-943XPurposeThe Chinese Children’s Cancer Group developed the CCCG-NB-2014 study to formulate optimal treatment strategies for high-risk (HR) neuroblastoma (NB). The safety and efficacy of this protocol were evaluated.MethodPatients with newly diagnosed neuroblastoma and defined as HR according to the Children’s Oncology Group study were included. They were treated with a combination of chemotherapy, surgery, and radiotherapy. The treatment-related toxicities, response rate, 3-year progression-free survival (PFS), and overall survival (OS) were analyzed.ResultsOf 159 patients enrolled between 2014 and 2018, 80 were eligible, including 19 girls and 61 boys, with a median age of 3.9 years (range 0.9–11). After a median follow-up of 24 months (range 3–40), the median OS was 31.8 months, and 3-year OS was 83.8%. In multivariate analyses, the OS was affected by N-MYC amplification (hazard ratio 0.212, 95% confidence interval (CI) 0.049–0.910; p = 0.037) and giant tumor mass (hazard ratio 0.197, 95% CI 0.071–0.552; p = 0.002). The median 3-year PFS was 25.8 months, and 3-year PFS was 57.5%. The univariate analysis showed that only the giant tumor mass was associated with the outcome. Of the 13 deaths, 11 died from the rapid progression of the disease and two from treatment-related toxicities. The most common adverse reaction was chemotherapy-induced hematological toxicity.ConclusionThe PFS and OS reported in our study were similar to Western countries. The CCCG-NB-2014 protocol proved to be an efficient regimen with tolerable side-effect for the treatment of pediatric HR-NB.Dongdong ZhangDongdong ZhangNatasha Mupeta KawemePeng DuanYouhong DongXiaojun YuanFrontiers Media S.A.articleneuroblastomahigh riskCCCG-NB-2014overall survivalN-mycNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	neuroblastoma high risk CCCG-NB-2014 overall survival N-myc Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	neuroblastoma high risk CCCG-NB-2014 overall survival N-myc Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Dongdong Zhang Dongdong Zhang Natasha Mupeta Kaweme Peng Duan Youhong Dong Xiaojun Yuan Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
description	PurposeThe Chinese Children’s Cancer Group developed the CCCG-NB-2014 study to formulate optimal treatment strategies for high-risk (HR) neuroblastoma (NB). The safety and efficacy of this protocol were evaluated.MethodPatients with newly diagnosed neuroblastoma and defined as HR according to the Children’s Oncology Group study were included. They were treated with a combination of chemotherapy, surgery, and radiotherapy. The treatment-related toxicities, response rate, 3-year progression-free survival (PFS), and overall survival (OS) were analyzed.ResultsOf 159 patients enrolled between 2014 and 2018, 80 were eligible, including 19 girls and 61 boys, with a median age of 3.9 years (range 0.9–11). After a median follow-up of 24 months (range 3–40), the median OS was 31.8 months, and 3-year OS was 83.8%. In multivariate analyses, the OS was affected by N-MYC amplification (hazard ratio 0.212, 95% confidence interval (CI) 0.049–0.910; p = 0.037) and giant tumor mass (hazard ratio 0.197, 95% CI 0.071–0.552; p = 0.002). The median 3-year PFS was 25.8 months, and 3-year PFS was 57.5%. The univariate analysis showed that only the giant tumor mass was associated with the outcome. Of the 13 deaths, 11 died from the rapid progression of the disease and two from treatment-related toxicities. The most common adverse reaction was chemotherapy-induced hematological toxicity.ConclusionThe PFS and OS reported in our study were similar to Western countries. The CCCG-NB-2014 protocol proved to be an efficient regimen with tolerable side-effect for the treatment of pediatric HR-NB.
format	article
author	Dongdong Zhang Dongdong Zhang Natasha Mupeta Kaweme Peng Duan Youhong Dong Xiaojun Yuan
author_facet	Dongdong Zhang Dongdong Zhang Natasha Mupeta Kaweme Peng Duan Youhong Dong Xiaojun Yuan
author_sort	Dongdong Zhang
title	Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
title_short	Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
title_full	Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
title_fullStr	Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
title_full_unstemmed	Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol
title_sort	upfront treatment of pediatric high-risk neuroblastoma with chemotherapy, surgery, and radiotherapy combination: the cccg-nb-2014 protocol
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/706ab05b14704fc5bdf3d6b3329b833c
work_keys_str_mv	AT dongdongzhang upfronttreatmentofpediatrichighriskneuroblastomawithchemotherapysurgeryandradiotherapycombinationthecccgnb2014protocol AT dongdongzhang upfronttreatmentofpediatrichighriskneuroblastomawithchemotherapysurgeryandradiotherapycombinationthecccgnb2014protocol AT natashamupetakaweme upfronttreatmentofpediatrichighriskneuroblastomawithchemotherapysurgeryandradiotherapycombinationthecccgnb2014protocol AT pengduan upfronttreatmentofpediatrichighriskneuroblastomawithchemotherapysurgeryandradiotherapycombinationthecccgnb2014protocol AT youhongdong upfronttreatmentofpediatrichighriskneuroblastomawithchemotherapysurgeryandradiotherapycombinationthecccgnb2014protocol AT xiaojunyuan upfronttreatmentofpediatrichighriskneuroblastomawithchemotherapysurgeryandradiotherapycombinationthecccgnb2014protocol
_version_	1718428558371586048

Upfront Treatment of Pediatric High-Risk Neuroblastoma With Chemotherapy, Surgery, and Radiotherapy Combination: The CCCG-NB-2014 Protocol

Ejemplares similares